title: Prognostic impact of progesterone receptor status combined with body mass index in breast cancer patients treated with adjuvant aromatase inhibitor.
abstract: Aromatase inhibitors have played a central role in endocrine therapy for the treatment of estrogen receptor (ER)-positive breast cancer in postmenopausal patients. However, prognostic factors for recurrence following such treatment have not been identified. The current study aimed to validate the prognostic value of endocrine-related progesterone receptor (PgR) status combined with body mass index (BMI). Among 659 consecutive patients with primary breast cancer who underwent curative surgery between 2002 and 2012, 184 postmenopausal patients with ER-positive (ER+) and human epidermal growth factor receptor type 2-negative (HER2-) breast cancer who were treated with adjuvant aromatase inhibitor therapy were assessed. The patients were assigned to groups based on BMI, according to the WHO cut-off value: ≥25 kg/m2(high, H) or <25 kg/m2(low, L). Positive nodal status, negative PgR status, BMI-H and a high Ki-67 labeling index (≥20%) were found to be significantly associated with a short recurrence-free interval (RFI) upon univariate analysis (P=0.048, 0.007, 0.027, and 0.012, respectively). The patients were further grouped based on their combined PgR/BMI status. The RFI was significantly shorter in the PgR- and/or BMI-H group compared with that of the PgR+/BMI-L group (P=0.012). Multivariate analysis revealed PgR- tumors and/or BMI-H and positive nodal status to be independent prognostic factors (P=0.012 and 0.020, respectively). The present findings indicate that PgR/BMI status may serve as a practical tool in the management of ER+ and HER2- breast cancer in patients treated with adjuvant aromatase inhibitors.
authors.affiliation: Department of Breast Surgery, Hiroshima Prefectural Hospital, Hiroshima 734-8530, Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Ohara
authors.affiliation: Department of Breast Surgery, Hiroshima Prefectural Hospital, Hiroshima 734-8530, Japan.
authors.forename: Etsushi
authors.initials: E
authors.lastname: Akimoto
authors.affiliation: Department of Breast Surgery, Hiroshima Prefectural Hospital, Hiroshima 734-8530, Japan.
authors.forename: Midori
authors.initials: M
authors.lastname: Noma
authors.affiliation: Department of Breast Surgery, Hiroshima Prefectural Hospital, Hiroshima 734-8530, Japan.
authors.forename: Kazuo
authors.initials: K
authors.lastname: Matsuura
authors.affiliation: Department of Clinical Oncology, Hiroshima Prefectural Hospital, Hiroshima 734-8530, Japan.
authors.forename: Mihoko
authors.initials: M
authors.lastname: Doi
authors.affiliation: Kagawa Breast Clinic, Hiroshima 730-0029, Japan.
authors.forename: Naoki
authors.initials: N
authors.lastname: Kagawa
authors.affiliation: Department of Breast Surgery, Hiroshima Prefectural Hospital, Hiroshima 734-8530, Japan.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Itamoto
keywords: aromatase inhibitor; body mass index; breast cancer; progesterone receptor